{
    "title": "Sanofi trial failure halts work on breast cancer treatment amcenestrant",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11118893/Sanofi-scraps-development-amcenestrant-breast-cancer-treatment.html",
    "date": "2022-08-17",
    "keywords": [
        "drug",
        "breast",
        "cancer",
        "sanofi",
        "zantac",
        "treatment",
        "trial",
        "opportunity",
        "pipeline",
        "market",
        "share",
        "company",
        "roche",
        "astrazeneca",
        "camizestrant",
        "burger",
        "work",
        "potential",
        "failure",
        "blow",
        "healthcare",
        "companys",
        "development",
        "move",
        "pressure",
        "multibillion",
        "seller",
        "eczema",
        "dupixent",
        "race",
        "dubbed",
        "ameera5",
        "amcenestrant",
        "monitoring",
        "panel",
        "close",
        "loss",
        "blue",
        "chip",
        "index",
        "cac40",
        "plaintiff",
        "lawsuit",
        "case",
        "range",
        "investor",
        "scare",
        "week",
        "cfo",
        "jeanbaptiste",
        "chatillon",
        "price",
        "rout",
        "undervaluation",
        "efanesoctocog",
        "alfa",
        "merit",
        "fraction",
        "march",
        "sanofis",
        "study",
        "diagnosis",
        "oncology",
        "asset",
        "credit",
        "suisse",
        "analyst",
        "jo",
        "walton",
        "combination",
        "ibrance",
        "group",
        "hormone",
        "therapy",
        "class",
        "oestrogen",
        "receptor",
        "response",
        "giredestrant",
        "faslodex",
        "design",
        "reporting",
        "hummel",
        "paris",
        "editing",
        "hardcastle",
        "bernadette",
        "baum"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}